Broader off-label coverage under Part D
Executive Summary
Sens. Dianne Feinstein, D-Calif., and Sam Brownback, R-Kan., urge broader access to off-label indications under Medicare Part D in a May 22 letter to the Senate Finance Committee. The senators, who co-chair the Senate Cancer Coalition, urge that Medicare legislation being drafted by the committee include a provision allowing Part D plans to consider the "full range" of evidence in making off-label coverage decisions and bring reimbursement standards for Part D "into line with coverage standards used under Medicare Part B and by commercial insurers." CMS is currently reviewing appropriate compendia for off-label coverage under Part B (1"The Pink Sheet," April 14, 2008, p. 15)
You may also be interested in...
CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July
CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.